The JAK3 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal epithelial cell line. This product delivers a heterogeneous pool of cells harboring targeted disruptions in the JAK3 gene, enabling loss-of-function studies in a human clear cell renal cell carcinoma (ccRCC) background. The polyclonal format captures a spectrum of mutations, providing a robust model system for examining JAK3-dependent signaling without relying on single-clone artifacts.
The 769-P parental line was established from a primary human clear cell renal cell carcinoma and serves as a widely used in vitro model for renal cancer biology. These epithelial cells retain key characteristics of ccRCC, including relevant oncogenic signaling networks and metabolic profiles. Their epithelial origin and tumorigenic background make them particularly suitable for studying kinase signaling and cytokine responsiveness in the context of renal malignancy.
JAK3 is a non-receptor tyrosine kinase that associates with the common gamma chain (IL2RG) and is activated by cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Upon ligand binding, receptor dimerization enables JAK3 transphosphorylation by JAK1, leading to phosphorylation of receptor tyrosine residues that recruit STAT5A and STAT5B. Phosphorylated STAT5 dimerizes and translocates to the nucleus to drive transcription of targets such as MYC, CCND1, and BCL2. Additional signaling through PI3K-AKT and MAPK pathways further promotes survival and proliferation. Negative regulators like SOCS proteins and PTPN11 modulate JAK3 activity.
In the 769-P renal cell carcinoma background, JAK3 knockout facilitates dissection of cytokine-mediated signaling events that may contribute to tumor immune evasion, proliferation, and resistance to therapy. Given the emerging understanding of JAK-STAT pathway involvement in ccRCC progression, this model provides a relevant platform to investigate how loss of JAK3 alters downstream STAT and AKT pathway activation in renal epithelial cells. The polyclonal nature of the knockout population allows assessment of heterogeneous cellular responses, mimicking the genetic variability observed in tumor environments.
Typical applications include phospho-signaling arrays, Western blot for JAK3 and phospho-STAT5, RT-qPCR for cytokine-responsive genes, and flow cytometry for cell surface markers. These polyclonal knockout cells are suitable for drug sensitivity assays with JAK inhibitors, cell proliferation and apoptosis assays, and comparative studies of IL-2 family cytokine signaling. For further details or custom projects, contact Ascent Research.
